Lifecycle Management of Analytical Methods and Procedures According to New USP and ICH Guidelines
: 11 Mar 2021 - 12 Mar 2021
Sector: Laboratory Equipment
Type: Conference - Virtual, Training, Seminar, Workshop
Results of analytical methods are used as the basis for important decisions during the development and manufacturing of pharmaceutical products. All regulatory agencies expect the regulated industry to have procedures in place to ensure suitable levels of reliability, accuracy, and precision of such methods. The procedures should cover lifecycle phases from design, development, validation to on-going routine use.
Managing analytical methods and procedures according to the lifecycle approach has been recommended in recent FDA guidance documents and stimuli articles published by the USP. For example, the recent FDA guidance “Analytical Procedures and Methods Validation for Drugs and Biologics” contains a section on Lifecycle Management of Analytical Procedures.
This 2-day workshop will explain the background to the new Analytical Procedure Lifecycle guidelines and give attendees the knowledge needed to implement recommended approaches. Interactive exercises will be included in the workshop.
- Learn about the regulatory background and recommendations for managing the lifecycle of analytical methods and procedures
- Understand current and future industry trends: the concept of lifecycle management of analytical methods, recent ICH guidance (ICH Q12), proposed USP General Chapter (Analytical Procedure Lifecycle), and Quality by Design (QbD) principles for method development and validation
- Learn how to plan, execute and document design, development, and validation of methods developed in-house
- Understand the principles of lifecycle management for compendial procedures and for managing method transfer
- Be able to develop a strategy for analytical procedure lifecycle management
- Understand risk management strategies throughout the procedure lifecycle
- Understand the concept of measurement uncertainty
- Be able to justify and document decisions about the type and extent of re-validation after method changes
- Be able to define and demonstrate FDA, EU, USP, and ICH compliance to auditors and inspectors
- Be able to develop inspection-ready documentation during on-going routine operation
- Understand what questions will be asked during audits and inspections and how to answer them